

CVs of the candidates for the Supervisory Board (agenda item 7.1 to 7.4)

7.1 Curriculum Vitae

Wolfgang F. Hofmann, MD

Personal data

Year of birth: 1968

Nationality: German

Independency: yes

Competences and experiences:

- Research and Development / Gene Therapy
- Biopharmaceutical Manufacturing
- Biopharma & Medical Technology
- Biotechnology
- Sales
- M&A / Corporate Venture Capital
- Capital Markets & Investor Relations
- Accounting / Income Statement
- Digitalization
- General Management
- Governance
- Corporate Restructuring & Organizational Restructuring
- Commercialization & Scaling Market Entry

Current occupation:

Chief Executive Officer, leon-nanodrugs GmbH, Munich, Germany

Career highlights:

Since 2025	leon-nanodrugs, Munich, Germany Chief Executive Officer
2024 – Present	Trailhead Biosystems, Cleveland, Ohio, USA Non-Executive Director
2023 – 2024	Fresenius Group, Bad Homburg, Germany Group Head of Technology and Innovation; Chairman, Fresenius Innovation Council (AI and Gene Therapy Boards)
2022 – 2023	Fresenius Group Group Head, Corporate Investments

2021 – 2022	Fresenius Group Head of Group Strategy and Corporate M&A
2019 – 2021	Fresenius Medical Care, Bad Homburg, Germany Global Head of Mergers & Acquisitions
2015 – 2018	Fresenius Medical Care SVP, Head of Integrated Care
2010 – 2015	Fresenius Medical Care CEO, Pharmaceuticals
2006 – 2010	Fresenius Medical Care VP, Pharmaceuticals
2005 – 2012	ANM Adaptive Neuromodulation GmbH, Cologne, Germany Founder, Investor & Board Member (Non-Executive)
1999 – 2005	Novartis, Basel / Atlanta / Frankfurt Various roles in Sales, Marketing, Development, Corporate VC & M&A (Pharma, MedTech & Consumer Health)
1995 – 1999	Dana-Farber Cancer Institute, Boston, USA Research Fellow, Gene Therapy
1995	University of Tuebingen Junior House Officer, Interventional Radiology & Emergency Medicine

Qualifications:

1988 – 1995	Heidelberg University Doctor of Medicine (MD)
1999	Harvard Business School Finance & Management
2019	The Johns Hopkins University School of Medicine Healthcare Management / Lean Six Sigma Green Belt Class

Current group mandates:

- Trailhead Biosystems, Cleveland, Ohio, USA – Non-Executive Director (not listed)

Other current mandates:

- Hoechst Tennis- und Hockey Club 1899, Frankfurt, Germany – President (nonprofit)

Previous mandates:

- ANM Adaptive Neuromodulation GmbH, Cologne, Germany –
Founder, Investor & Board Member (Non-Executive)

Last update: April 2026

7.2 Curriculum Vitae

Dr Duncan McHale

Personal data

Year of birth: 1966

Nationality: British

Independence: yes

Member of the Supervisory Board of Evotec

First appointment: 2024

Current term of office: General Annual Meeting 2024 – 2026

Committees: ESG Committee

Competences and experiences

Extensive experience in the Discovery and worldwide Development of medicines with a particular focus on translational medicine, early drug development and Personalized Medicine. Experience at large and medium pharmaceutical companies as well as multiple biotechnology companies. Worked across many therapeutic modalities including small molecule, large molecule, siRNA, cell therapies and oncolytic viruses. Worked across many different disease areas, including immunology, oncology, dermatology, gastroenterology, cardiology, neurology and bone diseases. Experience across multiple biomarker platforms including genetics, transcriptomics, proteomics, metabolomics and imaging. Executive leadership positions in the biopharmaceutical industry for more than 20 years, resulting in progressing over 25 programmes into first-in-human studies. Using a strong scientific background combined with broad clinical research expertise has driven significant changes in early drug development across multiple companies including use of biomarkers, adaptive trial designs, Bayesian statistics and PK PD modelling to inform dose predictions. A long-standing career as an early drug developer and Chief Medical Officer with deep experience in translational medicine and personalized healthcare. Experience of multiple partnership programmes with Pharma partners including membership of multiple steering committees on specific drug programmes and broader multi-company partnerships on technology development. Founded a drug development consultancy organization which has grown to over 40 FTEs in 7 years and as a consultant to multiple biotech companies from 2017 to 2024, have experience of raising capital, buy and sell due diligence, development of corporate strategy, business development strategy and possesses in-depth knowledge and experience in general management, data-enabled innovation and risk management.

Experience as a member of multiple public committees including government advisory committees on human genetics and emerging science and biotechnology as well as Medical Research Committees on stratified Medicine and Clinical Pharmacology. Experience drafting joint industry and regulatory drug development guidelines as a member of the ICH E15 and E16 committees. Have been a member of multiple joint steering committees managing partnerships.

Current occupation

Co-Founder and Senior Development Clinician Weatherden Limited, London, UK
Chair of Synaptra Bio Ltd

Career highlights

2017 – current	Weatherden Limited Founder and director
2018 – 2023	Evelo Biosciences Chief Medical Officer
2011 – 2017	UCB Pharma Global Head of Exploratory Development
2008 – 2011	AstraZeneca Vice President of Translational Sciences

Qualifications

2010 – 2015	University of Liverpool Professor of Clinical Pharmacology (visiting)
2000	University of Leeds PhD
1990 – 1991	University of Newcastle 1990: B.Med.Sci. (first class) 1991: Bachelor of Medicine and Bachelor of Surgery (medical degree)

Current mandates in listed companies

Evotec SE, Hamburg, Germany (*listed on the Frankfurt Stock Exchange and NASDAQ, New York*)
Member of the Supervisory Board

Previous mandates in public organizations (non-commercial)

- Member of UK Gov't **Emerging Science and Bioethics Advisory Committee**
- Member of the **UK Human Genetics Commission**
- Chair of **Medical Research Council Stratified Medicine Governance Committee**
- Member of **Medical Research Council Discovery Awards program Committee**
- Member of **Medical Research Council Clinical Training Fellowship (panel)**
- Member of **Medical Research Council Clinical Training Fellowship in Pharmacology (Steering Committee and panel)**

Previous Leadership Roles on Industry Committees

- Chair of the ABPI **UK Stratified Medicine Initiative**
- IMI lead on call for **Molecular Taxonomy of Human Disease**
- Chair of the **EFPIA Pharmacogenetics and Pharmacogenomics ad hoc working group.**
- European Industry Representative to the Genomic biomarker ICH working party and co Rapporteur for **ICH (International Conference on Harmonization) Expert Topic E15 and E16 (Genomic Biomarker Qualification Working group)**

Last update April 2026

7.3 Curriculum Vitae

Dieter Weinand

Personal data

Year of birth: 1962

Nationality: US-American

Independence: yes

Member of the Supervisory Board of Evotec

Designated first appointment: 2026

Designated term of office: 2026 – 2028

Competences and experiences

Dieter Weinand brings more than 30 years of leadership experience in the global pharmaceutical and biopharmaceutical industry. He has held senior executive and general management positions at leading multinational companies including Bristol Myers Squibb, Sanofi, Bayer and Pfizer with full P&L responsibility and broad international exposure.

Over the past five years, he has focused on Non-Executive Director roles, primarily supporting innovation-driven biotechnology companies. He has extensive experience in governance and chairmanship responsibilities across public and private organizations and is well regarded for his ability to act as an integrative Chair, providing strategic oversight while constructively supporting executive leadership teams, particularly during periods of transformation or operational challenge.

His sector expertise spans multiple therapeutic areas, including cardiology, oncology, pulmonology, dermatology, immunology, and inflammation. He combines deep scientific and commercial understanding with a strong belief in the strategic value of innovation as a primary driver of long-term company success.

Mr. Weinand has a proven track record in driving change management initiatives, business optimization, and performance improvement on a global scale. He has led major product launches and commercial transformations, strengthening accountability, execution discipline, and portfolio focus across diverse geographies and product lines.

He is known for his high-energy, results-oriented approach and his ability to contribute effectively at board level through strategic insight, independence of thought, and a strong international network of industry stakeholders and investors. Having lived and worked extensively in the United States, Latin America, Asia and Europe, he brings a truly global perspective. He has family ties to Germany, speaks basic German, and has a solid understanding of German business culture.

Mr. Weinand holds a B.A. in Biology from Concordia College, New York, and an M.S. in Pharmacology and Toxicology from Long Island University, New York.

Current occupation

Professional Non-Executive Board Member of Board of directors in various companies.

Career highlights

2018 – 2020	Sanofi Executive Vice President, Primary Care
2014 – 2018	Bayer President and Chief Executive Officer, Bayer Pharma
2013 – 2014	Otsuka President, Global Commercialization
2010 – 2013	Pfizer
2012 – 2013	President, Primary Care, Asia Pacific and Canada
2010 – 2012	President, Asia Pacific
2001 – 2010	Bristol Myers Squibb
2009 – 2010	President, Intercontinental
2005 – 2009	President, Latin America, Caribbean and Canada
2004 – 2005	Senior Vice President, Brand Commercialization, Global Marketing
2002 – 2004	Vice President, Neuroscience, Global Brand Champion, Abilify
2001 – 2002	Vice President, Global Marketing, Immunology, Inflammation, Pulmonology and Dermatology

Qualifications

1985 – 1987	Long Island University, Brooklyn, New York M.S. Pharmacology / Toxicology
1983 – 1984	New York Medical College, Valhalla, New York
1979 – 1982	Concordia College, Bronxville, New York B.A. Biology / Pre-Medicine

Current Board Affiliations

2018 – present	Replimune Group, Inc. (Public)
2023 – present	Confo Therapeutics NV (Private) (Chair)
2021 – present	Fore Biotherapeutics Inc. (Private) (Chair)
2024 – present	Disco Pharmaceuticals GmbH (Advisory Board) (Private)
2024 – present	Clasp Therapeutics, Inc. (Private) (Chair)
2025 – present	Sibylla Biotech S.p.A. (Private) (Chair)

Current Boards that will be exited throughout the year 2026:

2023 – present	Coya Therapeutics, Inc. (Public)
2025 – present	AstriVax Therapeutics NV (Private) (Chair)

Former Board Affiliations

2024 – 2026	Anaveon AG (Private) (Chair) (resigned in March 2023)
2025 – 2026 (May)	Orogen Therapeutics, Inc. (Private) (resignation is scheduled as of May 31)
2024 – 2025	Meliora Therapeutics (Private) (Chair)
2021 – 2026	Inspirna Inc. (Private) (Chair)
2021 – 2024	Mnemo Therapeutics SAS (Private) (Chair)
2020 – 2023	Reunion Neuroscience Inc. (Private)
2015 – 2019	HealthPrize Technologies LLC (Private)
2022 – 2024	Umoja Biopharma, Inc. (Private) (Chair)
2020 – 2022	Field Trip Health Inc. (Public)
2020 – 2024	Ziel Bio Inc. (Private)

Last update April 2026

7.4 Curriculum Vitae

Wesley P. Wheeler

Personal data

Year of birth: 1956

Nationality: US-American

Independence: yes

Member of the Supervisory Board of Evotec

First appointment: 2024

Current term of office: General Annual Meeting 2024 – 2026

Committees: Remuneration Committee

Competences and experiences

- 20+ years as CEO or President
- Corporate restructuring
- Biologic and small molecule manufacturing
- Drug development & regulatory compliance
- Logistics, depot management and biologic storage
- Clinical laboratory and clinical trials management
- Quality Assurance
- Operational turnarounds
- Marketing
- M&A and corporate integration
- Supply chain operations
- Procurement management
- Lean Six Sigma and Operational Excellence
- Engineering & construction management
- 12 years living / operating in foreign countries

Current occupation:

2024 – Present

CEO & Board Director, LabConnect Inc.

Career Highlights:**2019 – 2023****President, UPS Healthcare**

UPS Healthcare Division is a \$10 billion vertical business unit within UPS. The Healthcare Division, comprising 10,000 employees and managing over 17m square feet of GMP space in 35 countries, provides comprehensive logistics solutions - from clinical to commercial - throughout the world.

2011 – 2019**Chief Executive Officer & Director, Marken, a UPS Company**

Marken is a \$1billion leading specialty clinical supply chain company serving the global pharmaceutical and healthcare industries. Services include central lab specimens logistics, depot storage & distribution, direct to patient services, 4PL management, customs brokerage, kit building and clinical distribution project management. Marken serves 49,000 investigator sites in over 150 countries from 45 worldwide locations. The company was acquired by UPS in December, 2016.

2007 – 2010**President, Chief Executive Officer & Director, Patheon (now ThermoFisher)**

The pharmaceutical industry's leading contract manufacturing and formulation development company serving the pharmaceutical industry. Publicly traded on the TSX, now privately held and merged with DSM Pharma Products.

2003 – 2007**President, Valeant Pharmaceuticals International Inc. (now Bausch Health)**

Valeant is a leading specialty pharmaceuticals company. The company manufactures and sells products in several therapeutic categories. During this time, I was responsible for the North American business unit, global marketing, acquisitions and corporate development. Acquired Xcel Pharmaceuticals and several products during this period. I was responsible for the R&D division from 2006-2007, which included the late stage development of retigabine (Potiga).

2002 – 2003**Chief Executive Officer, DSM (now ThermoFisher)**

DSM is a leading manufacturing company based in the Netherlands. A subsidiary of DSM Pharmaceutical Products, based in Greenville, NC. The Greenville facility employed 1,200 people and was the third largest employer in Pitt County. Many important biological drugs were launched from this site and continue to supply the industry.

1989 – 2002

Senior Vice President – Manufacturing and Supply, GlaxoSmithKline

Responsibilities included the management of strategy and logistics for the global manufacturing & supply division, based in London and RTP. During this period, GSK consolidated all manufacturing, procurement and logistics under one central division and put in place a five year transformational change program which ultimately reduced the cost of goods with few sites and better processes. LeanSixSigma was introduced to GSK twice during this period.

1978 – 1989

Field Engineer, Cost & Schedule Engineer – ExxonMobil Corp

Qualifications:

1992

California Lutheran University
Master of Business Administration, Finance

1974 - 1978

Worcester Polytechnic Institute
BSME, Mechanical Engineering, with distinction

Current mandates in listed companies:

Evotec SE, Hamburg, Germany (*listed on the Frankfurt Stock Exchange and NASDAQ, New York*)

Member of the Supervisory Board

Current mandates in non-listed companies:

- Envirotainer – Director of the Board
- Argenta – Director of the Board

Other current mandates:

- Cairn Therapeutics – Investor / member of the Board
- Belhaven Biopharma – Investor / member of the Board

Last update: April 2026